Female reproductive system neoplasm

This early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with stan…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated che…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…

This study tests a new treatment called ADP-A2M4CD8, made from a patient's own immune cells, for ovarian cancer that has returned. It is given alone or with another drug (nivolumab) to see if it can shrink tumors. About 66 people with a specific genetic marker (HLA-A*02 and MAGE-…

This study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…

This study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…

This early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This phase II trial tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that is still present after initial treatment. About 35 women whose cancer was found during a second-look surgery will receive bevacizumab every…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This pilot study tests two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted enzyme blocker)—in women with platinum-resistant high-grade serous ovarian, fallopian tube, or peritoneal cancer. The goal is to see how these drugs, given alone and together, change immu…

This Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This Phase 3 trial compares a new drug, MK-2870, against standard treatments for people with recurrent or metastatic cervical cancer that has progressed after initial therapy. About 686 participants will receive either MK-2870 or a doctor-chosen standard treatment. The main goal …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It included 162 adults whose cancer had previously responded to platinum-based treatm…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…

This study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …

This early-phase trial tests a new type of cell therapy for people with recurrent solid tumors, especially ovarian cancer, that have a specific protein called MUC16 on their surface. The treatment involves collecting a patient's own immune cells, genetically modifying them to rec…

This study looks at whether adding Juice Plus+ supplements to the diet helps ovarian cancer patients who are in remission. About 75 participants will either take the supplements plus get dietary counseling, or receive counseling alone. Researchers will measure changes in blood ma…

This phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…

This phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether combining olaparib and temozolomide works better than standard drugs (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery and has stopped responding to initial chemotherapy. About 74 pa…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or sta…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests a combination of two drugs, alpelisib and fulvestrant, in people with a specific type of advanced uterine cancer (endometrioid endometrial cancer) that has a PIK3CA gene mutation. The goal is to see if the treatment can shrink or control the cancer. About 51 part…

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …

This Phase 3 trial is investigating whether the drug olaparib can help women with a specific type of ovarian cancer stay in remission longer. The study includes women whose cancer has returned but responded well to platinum-based chemotherapy, and who carry a BRCA gene mutation. …

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This trial investigates whether the immunotherapy drug avelumab, given alone or combined with talazoparib or axitinib, can shrink tumors or slow disease progression in women with recurrent or persistent endometrial cancer. Participants have specific tumor types, including those w…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase II trial tests whether simvastatin, a widely used cholesterol medication, can reduce the size of uterine fibroids and ease related symptoms. Researchers will give 60 women either simvastatin or a placebo daily for 12 weeks, measuring fibroid volume by ultrasound and tr…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a combination of three drugs—ALX148, liposomal doxorubicin, and pembrolizumab—in people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if blocking the CD47 protein on cancer cells can boost the immune syst…

This early-phase trial tests a new drug that targets a specific gene (EphA2) to slow tumor growth in people with advanced solid tumors that have spread or returned. About 49 participants will receive the drug to find the safest dose and check for side effects. The goal is to cont…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase 2 trial tests whether combining internal radiation (brachytherapy) with two immunotherapy drugs, durvalumab and tremelimumab, can help women with gynecologic cancers that are resistant to platinum chemotherapy. The study includes 9 participants with ovarian, endometria…

This Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors a…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This phase 2 trial tests whether combining a vaccine that targets the p53 protein (p53MVA) with the immunotherapy drug pembrolizumab can shrink tumors in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based ch…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This study tests whether a surgery that uses frozen sections to guide removal (Frozen-Section Directed Excision) works better than the usual wide local excision for high-grade vulvar dysplasia. About 112 adults with confirmed high-grade dysplasia will be randomly assigned to one …

This early-phase trial tests a new approach for people with advanced pancreatic or ovarian cancer that has not responded to standard treatments. Participants receive a single infusion of their own immune cells, engineered to recognize and attack cancer cells (huCART-meso), along …

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This trial tests a digital tool that helps doctors and patients manage cancer risks linked to hereditary syndromes like BRCA-related breast/ovarian cancer and Lynch syndrome. The tool provides personalized recommendations during primary care visits. Researchers compare care gaps,…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…

This trial tests whether adding a personalized vaccine and immune-boosting drugs to standard chemotherapy can help the body fight advanced ovarian cancer more effectively. Participants receive chemotherapy directly into the abdomen along with oral medication and injections of a v…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This phase 2 trial tests whether adding an experimental drug called etigilimab to the immunotherapy nivolumab can help control clear cell ovarian, fallopian tube, or primary peritoneal cancers that no longer respond to platinum chemotherapy. The study enrolls about 23 adults with…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This early-phase trial investigates whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be re-stimulated in the lab and infused back to fight platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Participants receive their r…

This Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involv…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study tests whether the drug olaparib, given before surgery, can shrink tumors in women with recurrent ovarian cancer that has come back after at least 6 months. About 71 participants will receive either olaparib or standard chemotherapy before surgery. Researchers will meas…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase trial tests a personalized cell therapy for advanced ovarian cancer. About 20 women will receive immune cells engineered to recognize and attack their cancer. The main goals are to check safety and see if the treatment shrinks tumors.

This early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard trea…

This phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This study tests whether the immunotherapy drug TSR-042 can help prevent cervical cancer from returning in patients with high-risk locally advanced disease who have completed standard chemo-radiation. About 134 women will receive TSR-042 as a maintenance therapy to see if it exte…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This phase 3 trial compares two chemotherapy approaches for people with germ cell tumors that have returned or not responded to initial treatment. One group receives standard-dose chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP). The other receives high-dose chemothe…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…

This phase 2 trial is testing a combination of nab-sirolimus (Fyarro) and fulvestrant (Faslodex) in 37 people with recurrent low-grade serous ovarian cancer. The goal is to see if the drugs can shrink tumors or stop them from growing. Participants receive the drugs intravenously …

This early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …

This study tests a drug called sacituzumab govitecan in 50 people with endometrial cancer that has returned or not responded to platinum chemotherapy. The drug works by delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or d…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests online adaptive radiotherapy, a type of radiation that adjusts in real-time to target cervical cancer more precisely. By using smaller treatment margins, doctors hope to reduce side effects while still effectively treating the tumor. The trial involves 30 adults …

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study was designed to test whether a new drug called M4344, combined with the PARP inhibitor niraparib, could be safe and effective for women with recurrent ovarian cancer that had stopped responding to PARP inhibitors. The plan was to enroll women with advanced ovarian, pri…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study tests whether adding a new immunotherapy drug (cadonilimab) to chemotherapy before the usual chemoradiation can shrink tumors better in people with locally advanced cervical cancer. About 29 participants will receive the combination, then standard treatment. The goal i…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This phase II trial tests whether adding pterostilbene, an antioxidant found in blueberries, to the hormone drug megestrol acetate can better slow endometrial cancer growth before hysterectomy. About 44 patients will receive either megestrol acetate alone or with pterostilbene fo…

This phase 2 trial tests a new drug called SKB264, given by IV every two weeks, in 20 women with recurrent ovarian epithelial cancer. It also looks at how the antibiotic clarithromycin affects SKB264 levels in the body. The main goals are to see if the drug shrinks tumors and to …

This study tested a combination of two drugs—mirvetuximab soravtansine and pembrolizumab—in 18 people with a specific type of uterine cancer (endometrial cancer) that had returned or persisted and was microsatellite stable (MSS). The goal was to see if the combo could shrink tumo…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for cervical cancer patients also receiving chemotherapy. The goal is to see if the shorter schedule is just as safe and effective, while reducing the number of hospit…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with relapsed ovarian cancer live longer. About 415 adults whose cancer returned in the abdomen after initial treatment will take part. The approach aims to control the di…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study compares two surgical approaches for women with middle-to-high risk endometrial cancer that hasn't spread beyond the uterus. One group gets sentinel lymph node sampling (removing only a few key nodes), while the other gets standard pelvic lymphadenectomy (removing many…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This Phase 3 trial compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature (dMMR). The goal is to see if pembrolizumab can better delay cancer growth and impro…

This study tests whether combining standard chemotherapy (cisplatin) and radiation with an immunotherapy drug (pembrolizumab) can shrink or control advanced vulvar cancer that cannot be removed by surgery. The trial includes 24 adults with unresectable, recurrent, or metastatic v…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests new MRI-based tools to make brachytherapy—a type of internal radiation—more accurate for gynecologic cancer. Researchers will compare standard brachytherapy with an MRI-guided version in 49 patients to see if it improves radiation delivery. The goal is better tum…

This study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This study looks at whether giving chemotherapy after surgery can help people with early-stage (stage I-II) endometrial cancer who have a higher risk of the cancer coming back. About 244 patients will either receive six cycles of carboplatin and paclitaxel or simply be observed. …

This study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…

This early-phase trial tests a new approach for people with ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard treatments. Patients receive their own T cells, which are genetically modified to recognize and attack cancer cells, along with…

This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix i…

This phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. While som…

This phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …

This Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests whether a low-caffeine green tea extract (EGCG) can shrink uterine fibroids and improve pregnancy and live birth rates in women aged 18-40 who have been trying to conceive for at least six months. Participants take the extract and are monitored for changes in fib…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests a new surgical technique to remove large uteri through the vagina using a sealed bag and electric fragmentation. The goal is to avoid abdominal scars and prevent the spread of tissue fragments. Twenty-five women aged 38 to 52 with large uteri are participating. T…

This study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The g…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a web-based tool called the Cancer Tracking System (CATSystem) that sends automated texts and alerts to help women in Kenya get timely cervical cancer screening and follow-up care. About 6,600 women across 10 hospitals will take part, with half the hospitals usin…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This study tests a fully enclosed protective bag used during laparoscopic myomectomy to remove uterine fibroids. The bag is meant to keep fibroid tissue completely isolated, preventing any leakage or spread during the procedure. Twenty women aged 28-46 with fibroids 6-10 cm will …

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…

This study tests a combination of two drugs, abemaciclib and letrozole, in people with advanced or recurrent endometrioid endometrial cancer that cannot be cured by surgery or radiation. The main goal is to see how many participants have no cancer growth after 6 months of treatme…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…

This phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease prog…

This early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Part…

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study looks at whether removing the fallopian tubes at the same time as a hysterectomy (for non-cancer reasons) can lower the chance of getting ovarian cancer later. About 4,400 women under 55 will be randomly assigned to have their tubes removed or not. Researchers will tra…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This study looks at whether a hormonal intrauterine device (IUD) alone or combined with the drug everolimus can treat precancerous changes or very early-stage endometrial cancer. About 100 women with these conditions will receive the IUD, and some will also take everolimus if the…

This study tests a new treatment for women whose ovarian cancer has come back. It combines chemotherapy and immunotherapy given directly into the abdomen with a drug given through a vein. The goal is to see if this approach can shrink or eliminate tumors. The study involves 24 pa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests whether a combination of surgery to remove visible tumors plus heated chemotherapy delivered directly into the abdomen can help people with ovarian cancer that has stopped responding to standard platinum-based chemo. About 140 adults with this type of recurrent o…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to se…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This early-phase trial aimed to test whether curcumin (the active compound in turmeric) could safely help treat cervical precancer (CIN3). It planned to give 500 mg of curcumin twice daily for 12 weeks to women with CIN3. However, the study was withdrawn before enrolling any part…

This phase 2 trial tests a drug called CYH33 in 93 women with recurrent ovarian, fallopian tube, or peritoneal clear cell carcinoma that has a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer grow. The main goal is to see if it shr…

This phase 3 study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this drug daily can delay the cancer from comin…

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of ut…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…

This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study was designed to test a new drug called BAT8006 in people with ovarian cancer that no longer responds to platinum-based chemotherapy. The drug works by targeting a protein on cancer cells to deliver a toxic payload directly. However, the study was withdrawn before any p…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This study tests whether a structured diet, exercise, and lifestyle program can help prevent uterine fibroids from returning after surgery. Researchers will follow 100 women aged 18-50 who recently had fibroids removed and are currently fibroid-free. The goal is to see if the pro…

This early-phase trial tests whether adding an immune-boosting drug (TSR-042) to standard radiation therapy is safe and effective for people with inoperable endometrial cancer. Ten participants with early-stage disease will receive both treatments. The goal is to see if the combi…

This phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalima…

This study compares two surgical methods for early-stage cervical cancer: minimally invasive (keyhole or robot-assisted) surgery and traditional open abdominal surgery. Researchers will follow 2000 patients for up to 5 years to see which approach leads to better survival and fewe…

This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…

This phase 2 study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and how safe it is. The trial is activ…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This phase 3 trial tests whether taking olaparib tablets daily can delay the return of advanced ovarian cancer in women with BRCA gene mutations. Participants had already responded to initial platinum chemotherapy. The study compares olaparib to a placebo over up to two years, me…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This study tests a drug called larotrectinib in children and young adults (up to age 30) with certain cancers that have a specific genetic change called a TRK fusion. The goal is to see if the drug can shrink solid tumors or control leukemia that has returned. The drug works by b…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current s…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is testing whether artificial intelligence can help ultrasound scans better detect ovarian cancer in postmenopausal women. About 100 women with certain types of ovarian cysts will have their ultrasound images analyzed by AI. The goal is to see if the AI can match or be…

This study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdr…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if…

This study evaluates different cervical cancer screening methods using HPV testing in Botswana, involving 3000 women aged 25 and older. Researchers compare HPV genotype restriction with visual inspection to find the most accurate way to detect high-grade cervical dysplasia. The g…

This study tests a new type of DCE-MRI that takes pictures faster and reduces blurring from movement. The goal is to see if it gives clearer images of gynecologic tumors than traditional MRI. About 24 women with gynecologic cancer and healthy volunteers will take part. The new sc…

This study looks at whether RNA in saliva can help tell the difference between ovarian cancer, borderline tumors, and benign cysts. Researchers are collecting saliva samples from 746 women before and after surgery. The goal is to find a simple, non-invasive way to speed up diagno…

This study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. …

This study explores whether a non-invasive electroacupuncture technique can detect signs of persistent viruses, like HPV and SARS-CoV-2, in 30 women with advanced cervical cancer. Researchers will measure electrical responses at specific body points to see if they match viral pre…

This study looks at whether offering HPV self-sampling kits by mail, pharmacy, or clinic can make cervical cancer screening easier. One thousand women aged 25-65 in Quebec will try different ways to get and return the kit. The goal is to see which method works best and if women f…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This trial tests two strategies for preventing cervical cancer in women living with HIV in Tanzania. Both strategies involve HPV self-sampling and visual checks of the cervix, but they differ in the timing of HPV vaccination. The study aims to see which approach better reduces pr…

This study in Malawi tests different methods—like in-person or virtual training, coaching, and visual reminders—to help health workers talk about and offer cervical cancer prevention to women and girls in HIV care. About 7,000 people will take part. The goal is to find the most e…

This study looks at two types of surgery to prevent ovarian cancer in women aged 30-50 who have gene mutations that raise their risk. One surgery removes both the fallopian tubes and ovaries, while the other removes only the tubes first and delays removing the ovaries. The goal i…

This trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…

This study tests whether removing the fallopian tubes during planned gallbladder removal surgery is safe for women aged 45 and older. The goal is to see if this extra step can help prevent ovarian cancer without causing more complications. About 300 women will take part, with hal…

This study looks at whether women in rural Uganda can screen themselves for cervical cancer using a simple HPV test at home. Over 2,500 women aged 25-49 will collect their own samples during community health campaigns. The goal is to see if this approach increases screening rates…

This study compares two ways to screen for cervical cancer: a Pap smear every 2.5 years versus an HPV test every 5 years. Over 76,000 women aged 25-69 in Australia are taking part, including those who received the HPV vaccine and those who did not. The goal is to see if the less …

This study looks at whether eating a diet high in magnesium can help prevent low blood magnesium levels in women with ovarian cancer who are receiving carboplatin chemotherapy. Low magnesium is a common side effect of this treatment. The study enrolled 26 participants and will me…

This study looks at whether giving women a free self-sampling device (SSD) through their general practitioner (GP) can increase cervical cancer screening rates among those who haven't had a smear test in 6 years. About 3,375 women aged 31-64 in Flanders will be randomly assigned …

This study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…

This study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This trial is testing whether watching educational videos before minimally invasive gynecologic surgery can lower patient anxiety. Participants are randomly assigned to either watch the videos or receive standard counseling alone. The study measures anxiety and preparedness throu…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study tests a program called ENABLE Cornerstone, where specially trained lay coaches provide support to family caregivers of people with advanced cancer. The coaches help caregivers manage stress, improve coping skills, and plan for the future through phone or in-person sess…

This study tests a workshop called HOPE designed to reduce feelings of hopelessness and helplessness in patients with recurrent ovarian cancer. Sixty participants will either attend the workshop or receive usual care. Researchers will measure whether the workshop is feasible, acc…

This study tests whether yoga therapy can improve physical and emotional well-being in people with cervical cancer undergoing chemotherapy and radiation. About 40 participants with stage IB2 to IIIB cervical cancer will attend yoga classes or receive a DVD. The main goal is to se…

This study tests whether a telemedicine program is a practical way to address the unique needs of adults aged 70 and older who are receiving cancer treatment. Participants meet with a geriatric nurse via video calls over three months to discuss symptoms and aging-related concerns…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a newer type of radiation therapy called online adaptive radiotherapy (oART) for people who have had surgery for endometrial or cervical cancer. The goal is to see if using smaller treatment margins can reduce side effects while still effectively targeting any re…

This study looks at whether providing food assistance—like vouchers, grocery delivery, or a hospital food pantry—helps cancer patients finish their treatment. About 600 patients with breast cancer who struggle to afford food will be randomly assigned to one of three programs. Res…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether applying an ice pack to the lower abdomen after vNOTES hysterectomy can lower pain and reduce the need for painkillers. 122 women having surgery for benign conditions will be randomly assigned to receive either standard care or standard care plus ice pack…

This study tests whether a 12-week health education program can improve lifestyle, quality of life, and mental health in 28 women with cervical cancer. Participants receive a booklet and attend meetings and social media sessions covering exercise, diet, self-esteem, and more. The…

This Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…

This study tests whether group or one-on-one peer support helps Black patients with endometrial cancer complete their treatment and feel less isolated. About 252 participants will be randomly assigned to group support, one-on-one peer calls, or usual care. The main goal is to see…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This pilot study tested whether kava, a herbal supplement, could safely reduce anxiety and stress in 43 cancer survivors who had completed treatment. Participants took either kava or a placebo for 14 days, then switched after a washout period. The trial is currently suspended, an…

This study tests whether using a special monitor (ANI) during ovarian cancer surgery to guide pain medicine can lower the chance of chronic pain three months after the operation. About 126 women having open surgery for ovarian cancer will be randomly assigned to standard care or …

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer manage their fears about the future. The program is delivered through video sessions and includes coping strategies. The study will enroll 42 patients to see if the program is pr…

This study tests an online program called Day by Day for women with stage III or IV gynecologic cancer who have high fear of their cancer getting worse or coming back. The program teaches skills to manage anxiety and reframe worries. About 23 women will try the program for 12 wee…

This study tests whether giving vitamin C through an IV before and during a hysterectomy can reduce blood loss. Forty women with fibroids or adenomyosis will receive either vitamin C or a placebo. Researchers will measure blood loss during surgery and check if vitamin C helps mai…

This pilot study tests whether a personalized home exercise program is practical and helpful for women with advanced ovarian cancer who are receiving chemotherapy before surgery. Twenty-two participants will follow daily exercises and weekly coaching until their operation. The ma…

This study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…

This study looks at whether a 10-week exercise program done at home can improve physical fitness in women who have finished treatment for endometrial cancer. Ten participants will do exercises like chair stands and arm curls, guided by video coaching. The goal is to see if this a…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study looks at risk factors for endometrial cancer in Black women, a group that may face different risks. Researchers will compare women recently diagnosed with the cancer to healthy volunteers, using questionnaires and interviews. The goal is to understand what factors matt…

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if the…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study aims to learn more about how inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, affect the risk of developing breast and ovarian cancer. Researchers will follow participants with a family history of these cancers, tracking their medical history and fa…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as wel…

This study enrolled over 78,000 women to see if regular screening with ultrasound and blood tests can lower the number of deaths from ovarian cancer. Participants were randomly assigned to either receive screening or usual care. The goal is to find out if catching the cancer earl…

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…

This study tested whether custom 3D printed applicators could improve radiation delivery in brachytherapy for gynecological cancers. Thirteen patients with cervical, uterine, vaginal, or vulvar cancer received MRI-guided treatment using these personalized tools. The goal was to s…

This study looks at how people with both cancer and heart failure feel day-to-day. Researchers will ask 100 participants about their symptoms and quality of life using simple questionnaires. No new treatments are tested—the goal is to better understand the challenges these patien…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, col…

This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researcher…

This study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This early-phase trial is testing the drug triapine in 12 women with a rare and aggressive type of uterine cancer called uterine serous adenocarcinoma. Participants receive a single dose of triapine before their scheduled hysterectomy, and researchers analyze tissue samples to se…

This study gives questionnaires to patients, interpreters, and healthcare professionals to understand how language and cultural differences impact care for women with gynecologic cancer. The goal is to identify barriers and improve the patient experience. About 45 people will tak…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at whether combining PET/MRI scans with blood and tumor tissue tests can create a detailed profile of high-grade serous ovarian cancer. The goal is to better predict how tumors respond to treatment, which could help doctors personalize care. The study involves 10…

This study follows about 700 women for up to 12 years after they had a uterine-sparing fibroid treatment, such as myomectomy or uterine artery embolization. Researchers want to see how long these treatments last before another procedure is needed, and how women's symptoms and qua…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study collects information from over 13,000 women treated for ovarian cancer at 18 French cancer centers. Researchers will look at patient details, tumor types, and treatments given to see how care has evolved since 2011. The goal is to understand what treatments are used an…

This study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better p…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at whether offering genetic testing to family members of people with hereditary breast and ovarian cancer syndrome helps more relatives learn about their own cancer risk. Researchers will follow 118 participants and their relatives to see how many choose to get t…

This study analyzes data from over 45,000 people diagnosed with colon or ovarian cancer in England between 2016 and 2017. Researchers are looking for differences in how quickly people are diagnosed and what treatments they receive, based on their socioeconomic status. The goal is…

This study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 people who are currently cancer-free will answer questionnaires about their quality of life, anxiety, sexual health, and more. The goal is to learn what matt…

This study aims to find biological markers (biomarkers) that show which cervical cancers have low oxygen levels, making them harder to treat with standard radiation. About 30 patients with advanced cervical cancer will have special MRI scans and tumor biopsies before and during t…

This study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…

This study examines genetic mutations in 20 people with serous borderline ovarian tumors, a low-risk type of ovarian growth. Researchers compare tumors with and without implants (spread) to see if certain gene changes predict a higher chance of recurrence. The goal is to learn wh…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This nationwide registry follows 578 women with uterine fibroids who choose either radiofrequency ablation (Acessa) or myomectomy. Researchers track symptom changes, quality of life, and need for repeat treatment over three years. The goal is to understand which procedure provide…

This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study is testing whether a special PET scan dye called 18F-FAZA can measure low oxygen levels (hypoxia) in cervix cancer tumors. About 30 adults with cervix cancer will receive the dye before starting standard treatment with radiation and chemotherapy. The goal is to see if …

This study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drug…

This study measures oxygen levels inside cervical cancer tumors during a type of radiation called brachytherapy. Ten adult patients with cervical cancer will have tiny oxygen sensors placed in their tumors during the procedure. The goal is to see if oxygen levels relate to how we…

This study aims to find the genetic changes that cause some women to have repeated molar pregnancies (abnormal growths in the womb). Researchers will analyze DNA from blood and tissue samples of up to 100 women and their relatives. The goal is to discover new genes linked to this…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal …

This study looks at how a person's genes and medical history might help predict nerve damage caused by chemotherapy. Researchers will follow 300 people with certain cancers who are scheduled for specific chemo drugs. The goal is to find patterns that could help prevent or reduce …

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…

This study looks at how diet, lifestyle, and genetics influence the risk of endometrial cancer. Researchers will compare women who have or had the cancer with those who do not, using surveys and genetic analysis. The goal is to identify factors that may increase or decrease risk,…

This phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while s…

This study watches a single gynecology resident as they learn to perform a hysterectomy through the vagina using a special camera, leaving no belly scars. The goal is to see how quickly the resident improves, measuring surgery time and any complications. Nineteen women with benig…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…

This study tracks how the tumor and nearby organs move during radiotherapy for cervix cancer. By taking many MRI scans during treatment, researchers hope to better target the tumor and spare healthy tissue. The goal is to reduce side effects and improve outcomes. The study involv…

This study looks at whether oxygen levels and internal pressure in cervical tumors can help predict how well radiation therapy works. Researchers measured these factors in 346 patients with cervical cancer before and during treatment. The goal is to understand why some tumors res…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study looks at how low oxygen levels and fluid pressure inside cervical cancer tumors relate to how well radiation therapy works. Researchers will measure these factors in 500 patients before and during treatment. The goal is to find the best way to identify which patients m…

This study looks at people with advanced ovarian cancer who have a second look laparoscopy after finishing their first chemotherapy. Doctors want to compare health outcomes between those who still have small amounts of cancer left and those who don't. They also want to see if thi…

This study uses artificial intelligence to analyze data from over 1,000 people with advanced ovarian cancer. The goal is to create a tool that helps doctors decide whether to perform surgery right away or after chemotherapy. The research combines information from a previous clini…

This early-phase study tests whether taking a low dose of aspirin daily for two weeks before surgery can change the immune environment of the fallopian tubes. Researchers will compare tissue from 18 women who take aspirin to control samples, looking for signs of reduced inflammat…

This study aimed to create a web-based decision aid for people invited to cancer screening in Sweden. The tool would provide clear information about the benefits and harms of screening, helping individuals decide based on knowledge rather than fear. The study was withdrawn before…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study collects information from about 300 endometrial cancer patients across Asia to see how doctors use cancer cell features to choose treatments. The goal is to learn which patients need stronger therapy and which can avoid extra side effects. No new treatments are tested—…

This pilot study aimed to see if a mobile health app could help track symptoms and quality of life in people with recurrent head and neck or gynecologic cancers. Participants would have used the app to report their feelings, side effects, and barriers to care. However, the study …

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study tests a program called the Sexual Health Empowerment (SHE) Project for women who are about to leave jail. The goal is to improve their understanding of cervical cancer, breast cancer, contraception, and sexually transmitted diseases. About 279 women will take part, and…

This study checks for muscle loss (sarcopenia) in 25 women with advanced ovarian cancer before they start chemotherapy. Using CT scans, researchers want to see how common this condition is and if it affects treatment timing. The goal is to better understand how muscle health rela…

This study looks at whether doctors can safely remove fewer lymph nodes during surgery for endometrial cancer by using a quick lab test during the operation. The goal is to reduce side effects like pain and swelling while still catching cancer that has spread. About 400 women wit…

This study looks at whether surgically removing uterine fibroids (myomectomy) changes blood flow in the main uterine artery. Researchers will use Doppler ultrasound to measure blood flow before and about 40 days after surgery in 70 premenopausal women. The goal is to provide new …

This study enrolls 2,300 Kenyan women and girls to improve cervical cancer prevention. Women provide self-collected swabs for HPV testing and undergo standard visual screening. The goal is to see if self-testing is as good as or better than current methods, and to understand what…

This study looks at whether offering cervical cancer screening in the emergency department helps more people get tested. About 200 women and transgender/non-binary individuals with a cervix, aged 25-65, will be offered a self-sampling kit or clinic referral. Researchers will call…

This study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…

This study looks at whether long-term inflammation raises the risk of endometrial cancer. Researchers are collecting blood and urine samples from 191 women having hysterectomy for either cancer or non-cancer reasons. They will compare markers of inflammation to better understand …